查Ganoderma lucidum的活性成分并解读其分子机制以改善学习和记忆障碍
Xiao-Tian Zhang1, Chun-Lei Ji2, Yu-Juan Fu2
1Department of Clinical Laboratory, The Second Hospital of Jilin University, Changchun, Jilin 130000, People's Republic of China.
Bioscience reports
|June 21, 2024
概括
光 (GL) 在改善学习和记忆障碍 (LMI) 方面表现有前途. 它的活性化合物可能通过向阿尔茨海默病等途径和调节瘤缩因子 (TNF) 来起作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 学习和记忆障碍 (LMI) 是一种普遍存在的中枢神经系统疾病.
- 光 (GL) 越来越多地被认为具有缓解LMI症状的潜力.
研究的目的:
- 为了研究Ganoderma lucidum在改善学习和记忆障碍方面的活性成分和分子机制.
- 确定GL对LMI治疗作用中的关键目标和途径.
主要方法:
- 使用TCMSP,BATMAN-TCM,GeneCards和DrugBank数据库对活性成分和标进行选.
- 构建"活性成分-标"和蛋白质-蛋白质相互作用 (PPI) 网络.
- 基因本体学 (GO) 功能丰富和KEGG通路分析使用DAVID.
- 瘤亡因子 (TNF) 蛋白质通过西方布洛特的验证.
主要成果:
- 确定了GL中的21个活性成分和142个相应的目标,其中59个是LMI的共同目标.
- GO分析揭示了448个生物过程,KEGG分析确定了55个与GL对LMI影响相关的信号通路.
- 阿尔茨海默病途径显示了最高的相关性,TNF被确定为关键蛋白质,经过实验验证.
结论:
- 光通过大约10种活性成分改善LMI.
- 治疗效果很可能是通过调节阿尔茨海默病途径和瘤缩因子 (TNF) 蛋白调节的.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
9.8K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
